Lexicon Pharmaceuticals (LXRX) Receives a Hold from Cowen & Co.

By Austin Angelo

In a report released yesterday, Chris Shibutani from Cowen & Co. maintained a Hold rating on Lexicon Pharmaceuticals (NASDAQ: LXRX). The company’s shares closed yesterday at $8.49, close to its 52-week low of $7.42.

According to TipRanks.com, Shibutani is a 3-star analyst with an average return of 2.6% and a 37.3% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Pieris Pharmaceuticals, and Nektar Therapeutics.

Lexicon Pharmaceuticals has an analyst consensus of Hold.

See today’s analyst top recommended stocks >>

Based on Lexicon Pharmaceuticals’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $34.71 million. In comparison, last year the company had a GAAP net loss of $30.72 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. It also offers programs in clinical development for diabetes, irritable bowel syndrome, and carcinoid syndrome.